glp 1 bmi range GLP-1 Prescriptions Quadruple Since 2021 Alongside Decline In Obesity The GLP-1 Access Gap: Mapping

Dimethylamine formation in man

The science is evolving rapidly, with multiple high-quality studies published in leading peer-reviewed journals consistently suggesting that GLP-1 therapy may offer meaningful protective effects against a range of obesity-related malignancies through mechanisms that operate both dependently and independently of weight loss

Neither cagrilintide nor retatrutide is FDA-approved for the use described here as of June 2026

DieboldSMoellmannJKahlesFHaj-YehiaELiehnEANickelAet alMyocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity